US20010007031A1 - 8-aminoquinolines - Google Patents
8-aminoquinolines Download PDFInfo
- Publication number
- US20010007031A1 US20010007031A1 US09/155,509 US15550999A US2001007031A1 US 20010007031 A1 US20010007031 A1 US 20010007031A1 US 15550999 A US15550999 A US 15550999A US 2001007031 A1 US2001007031 A1 US 2001007031A1
- Authority
- US
- United States
- Prior art keywords
- amino
- composition
- methyl
- compound
- primaquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000005012 8-aminoquinolines Chemical class 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 30
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 claims abstract description 15
- -1 tri-substituted phenoxy Chemical group 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 47
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 40
- 229960005179 primaquine Drugs 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 34
- UEFVAUCKVCFRDW-UHFFFAOYSA-N 4-n-[5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinolin-8-yl]pentane-1,4-diamine Chemical compound COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 UEFVAUCKVCFRDW-UHFFFAOYSA-N 0.000 claims description 32
- 201000004792 malaria Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 201000000317 pneumocystosis Diseases 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 12
- 230000000078 anti-malarial effect Effects 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 208000004554 Leishmaniasis Diseases 0.000 claims description 11
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 231100000440 toxicity profile Toxicity 0.000 claims description 11
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 230000003071 parasitic effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 239000003430 antimalarial agent Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 230000001099 anti-trypanosomal effect Effects 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 201000002311 trypanosomiasis Diseases 0.000 claims description 3
- UEFVAUCKVCFRDW-CQSZACIVSA-N (4r)-4-n-[5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinolin-8-yl]pentane-1,4-diamine Chemical group COC1=CC(N[C@H](C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 UEFVAUCKVCFRDW-CQSZACIVSA-N 0.000 claims description 2
- PCPLOIHDOZYKEW-UHFFFAOYSA-N 1-n-[6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)quinolin-8-yl]hexane-1,5-diamine Chemical compound COC1=CC(NCCCCC(C)N)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1Cl PCPLOIHDOZYKEW-UHFFFAOYSA-N 0.000 claims description 2
- NHXDJZNLZJMUSI-UHFFFAOYSA-N 1-n-[6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)quinolin-8-yl]pentane-1,4-diamine Chemical compound COC1=CC(NCCCC(C)N)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1Cl NHXDJZNLZJMUSI-UHFFFAOYSA-N 0.000 claims description 2
- UULZVETWCOAXRV-UHFFFAOYSA-N 4-n-[6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)quinolin-8-yl]hexane-1,4-diamine Chemical compound C12=C(C)C=CN=C2C(NC(CCCN)CC)=CC(OC)=C1OC1=CC(Cl)=C(Cl)C=C1Cl UULZVETWCOAXRV-UHFFFAOYSA-N 0.000 claims description 2
- YTGQDZXZIKBNRQ-UHFFFAOYSA-N 4-n-[6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)quinolin-8-yl]pentane-1,4-diamine Chemical compound COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1Cl YTGQDZXZIKBNRQ-UHFFFAOYSA-N 0.000 claims description 2
- HUMMHDCBVCHNDO-UHFFFAOYSA-N 4-n-[6-methoxy-4-methyl-5-(2,4,6-trichlorophenoxy)quinolin-8-yl]pentane-1,4-diamine Chemical compound COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=C(Cl)C=C(Cl)C=C1Cl HUMMHDCBVCHNDO-UHFFFAOYSA-N 0.000 claims description 2
- ALKOZIVZPWIMIZ-UHFFFAOYSA-N 4-n-[6-methoxy-4-methyl-5-[2,4,5-tris(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine Chemical compound COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(C(F)(F)F)=C(C(F)(F)F)C=C1C(F)(F)F ALKOZIVZPWIMIZ-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- VIHBKBYCXOKPPE-UHFFFAOYSA-N 4-n-[6-methoxy-4-methyl-5-[2,4,5-tris(trifluoromethyl)phenoxy]quinolin-8-yl]-1-n-propan-2-ylpentane-1,4-diamine Chemical compound COC1=CC(NC(C)CCCNC(C)C)=C2N=CC=C(C)C2=C1OC1=CC(C(F)(F)F)=C(C(F)(F)F)C=C1C(F)(F)F VIHBKBYCXOKPPE-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 13
- 230000002141 anti-parasite Effects 0.000 abstract description 5
- 239000003096 antiparasitic agent Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003473 anti-pneumocystis Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 244000045947 parasite Species 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 0 *C1=NC2=C(C(C)=C1)C(OC1=CC(C(F)(F)F)=CC=C1)=C(OC)C=C2NC(C)CCCN.CCCCC(C)NC1=CC(OC)=CC2=C1N=CC=C2.CCCCCOC1=C(OC)C=C(NC(C)CCCN)C2=C1C(C)=CC=N2.COC1=C(OC2=C(C)C(C)=C(C)C=C2)C2=C(N=CC=C2C)C(NC(C)CCCN)=C1 Chemical compound *C1=NC2=C(C(C)=C1)C(OC1=CC(C(F)(F)F)=CC=C1)=C(OC)C=C2NC(C)CCCN.CCCCC(C)NC1=CC(OC)=CC2=C1N=CC=C2.CCCCCOC1=C(OC)C=C(NC(C)CCCN)C2=C1C(C)=CC=N2.COC1=C(OC2=C(C)C(C)=C(C)C=C2)C2=C(N=CC=C2C)C(NC(C)CCCN)=C1 0.000 description 7
- 241000224017 Plasmodium berghei Species 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001445 schizonticidal effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 206010001935 American trypanosomiasis Diseases 0.000 description 5
- 241000178949 Leishmania chagasi Species 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- UVRMQLRUPDANMK-UHFFFAOYSA-N C.CCC(C)C.CCC(C)C Chemical compound C.CCC(C)C.CCC(C)C UVRMQLRUPDANMK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VWFHXOIAXIAYQN-UHFFFAOYSA-N butanedioic acid;4-n-[5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinolin-8-yl]pentane-1,4-diamine Chemical compound OC(=O)CCC(O)=O.COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 VWFHXOIAXIAYQN-UHFFFAOYSA-N 0.000 description 4
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- INDBQLZJXZLFIT-LLVKDONJSA-N (4r)-4-n-(6-methoxyquinolin-8-yl)pentane-1,4-diamine Chemical compound N1=CC=CC2=CC(OC)=CC(N[C@H](C)CCCN)=C21 INDBQLZJXZLFIT-LLVKDONJSA-N 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- UJSHLVKSGHOLME-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-nitroquinoline Chemical compound COC1=CC([N+]([O-])=O)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 UJSHLVKSGHOLME-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000222722 Leishmania <genus> Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000009182 Parasitemia Diseases 0.000 description 3
- 241000233872 Pneumocystis carinii Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000223104 Trypanosoma Species 0.000 description 3
- JJSCUXAFAJEQGB-MRVPVSSYSA-N [(1r)-1-isocyanatoethyl]benzene Chemical compound O=C=N[C@H](C)C1=CC=CC=C1 JJSCUXAFAJEQGB-MRVPVSSYSA-N 0.000 description 3
- 229960001413 acetanilide Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940047766 co-trimoxazole Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000029080 human African trypanosomiasis Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 201000002612 sleeping sickness Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YCKNFVJXYNVQFC-UHFFFAOYSA-N 2-[4-[[5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinolin-8-yl]amino]pentyl]isoindole-1,3-dione Chemical compound COC1=CC(NC(C)CCCN2C(C3=CC=CC=C3C2=O)=O)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 YCKNFVJXYNVQFC-UHFFFAOYSA-N 0.000 description 2
- UAYQMUMKYZXFLT-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-4-methoxy-2-nitroaniline;hydrochloride Chemical compound Cl.COC1=CC([N+]([O-])=O)=C(N)C=C1OC1=CC=C(Cl)C(Cl)=C1 UAYQMUMKYZXFLT-UHFFFAOYSA-N 0.000 description 2
- LGMMMSLCKZGPKN-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinolin-8-amine Chemical compound COC1=CC(N)=C2N=CC=C(C)C2=C1OC1=CC=C(Cl)C(Cl)=C1 LGMMMSLCKZGPKN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WOQOTMAWPGYSPR-UHFFFAOYSA-N C.C.CC(C)C.CCC(C)C Chemical compound C.C.CC(C)C.CCC(C)C WOQOTMAWPGYSPR-UHFFFAOYSA-N 0.000 description 2
- ZXKBGHHPIDTBFX-UHFFFAOYSA-N COC1=CC(NC(C)(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1 Chemical compound COC1=CC(NC(C)(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1 ZXKBGHHPIDTBFX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000222724 Leishmania amazonensis Species 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 241000233870 Pneumocystis Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940058934 aminoquinoline antimalarials Drugs 0.000 description 2
- 230000002514 anti-leishmanial effect Effects 0.000 description 2
- 230000001938 anti-toxoplasmal effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- RVAKDGYPIVSYEU-UHFFFAOYSA-N n',n'-diethyl-n-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine Chemical compound C1=CN=C2C(NCCCCCCN(CC)CC)=CC(OC)=CC2=C1C RVAKDGYPIVSYEU-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- INDBQLZJXZLFIT-NSHDSACASA-N (4s)-4-n-(6-methoxyquinolin-8-yl)pentane-1,4-diamine Chemical compound N1=CC=CC2=CC(OC)=CC(N[C@@H](C)CCCN)=C21 INDBQLZJXZLFIT-NSHDSACASA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DPATUMDQWSJANG-UHFFFAOYSA-N 2-(4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(=O)C)C(=O)C2=C1 DPATUMDQWSJANG-UHFFFAOYSA-N 0.000 description 1
- LDKKYYSDTRQIQE-UHFFFAOYSA-N 2-[4-[[5-(3,4-dichlorophenoxy)-6-methoxy-1-methyl-2h-quinolin-8-yl]amino]pentyl]isoindole-1,3-dione Chemical compound COC1=CC(NC(C)CCCN2C(C3=CC=CC=C3C2=O)=O)=C2N(C)CC=CC2=C1OC1=CC=C(Cl)C(Cl)=C1 LDKKYYSDTRQIQE-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- QISCTRCBADUWSD-UHFFFAOYSA-N 4-n-(6-methoxy-4-methylquinolin-8-yl)pentane-1,4-diamine Chemical class N1=CC=C(C)C2=CC(OC)=CC(NC(C)CCCN)=C21 QISCTRCBADUWSD-UHFFFAOYSA-N 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- ZQZHWRMJRAFZRB-UHFFFAOYSA-N C.C.CCCC Chemical compound C.C.CCCC ZQZHWRMJRAFZRB-UHFFFAOYSA-N 0.000 description 1
- WDQCHCWLIPRZMX-UHFFFAOYSA-N C.CCCC Chemical compound C.CCCC WDQCHCWLIPRZMX-UHFFFAOYSA-N 0.000 description 1
- SEHKZHHBXIDYNW-UHFFFAOYSA-M C=CC(C)=O.COC1=C(Cl)C=C(N)C=C1.COC1=C(Cl)C=C(NC(C)=O)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C2=C(N=CC=C2C)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C=C(C)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C=C(NC(C)=O)C([N+](=O)[O-])=C1.Cl.NN.OC1=CC=C(Cl)C(Cl)=C1.O[K].[Pd] Chemical compound C=CC(C)=O.COC1=C(Cl)C=C(N)C=C1.COC1=C(Cl)C=C(NC(C)=O)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C2=C(N=CC=C2C)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C=C(C)C([N+](=O)[O-])=C1.COC1=C(OC2=CC=C(Cl)C(Cl)=C2)C=C(NC(C)=O)C([N+](=O)[O-])=C1.Cl.NN.OC1=CC=C(Cl)C(Cl)=C1.O[K].[Pd] SEHKZHHBXIDYNW-UHFFFAOYSA-M 0.000 description 1
- ITUZEVGZEPVENV-UQKRIMTDSA-N COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1.COC1=CC(N[C@@H](C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1 Chemical compound COC1=CC(NC(C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1.COC1=CC(N[C@@H](C)CCCN)=C2N=CC=C(C)C2=C1OC1=CC(Cl)=C(Cl)C=C1 ITUZEVGZEPVENV-UQKRIMTDSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000224028 Plasmodium cynomolgi Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035660 Pneumocystis Infections Diseases 0.000 description 1
- 206010073756 Pneumocystis jirovecii infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- JJSCUXAFAJEQGB-QMMMGPOBSA-N [(1s)-1-isocyanatoethyl]benzene Chemical compound O=C=N[C@@H](C)C1=CC=CC=C1 JJSCUXAFAJEQGB-QMMMGPOBSA-N 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000005010 aminoquinolines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000000646 gametocidal effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- OTKXKTIRANPSHM-UHFFFAOYSA-N silver;methanamine;nitrate Chemical class [Ag+].NC.[O-][N+]([O-])=O OTKXKTIRANPSHM-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000002191 sporontocidal effect Effects 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to new compositions useful in treating parasitic and opportunistic infections. Additionally, the present invention relates to the use of enantiomers of 8-aminoquinoline compounds for the treatment of Pneumocystis carinii, pneumonia (PCP), toxoplasmosis, malaria, trypanosomaiasis, and leishmaniasis in mammals and the prevention of PCP and malaria in mammals.
- PCP Pneumocystis carinii, pneumonia
- toxoplasmosis malaria
- trypanosomaiasis trypanosomaiasis
- leishmaniasis in mammals and the prevention of PCP and malaria in mammals.
- Parasitic diseases are a major health problem in the world. Malaria, due to one of four Plasmodium species, is the most widespread parasitic disease, with a reported total of 100 million clinical cases that lead to more than 1 million deaths annually. Trypanosomiases are diseases caused by the protozoa of the genus Trypanosoma. Two major forms of this disease occur in man: African trypanosomiasis (sleeping sickness) and American trypanosomiasis (Chagas disease). Some 16-18 million people are infected with T. cruzi, the cause of American trypanosomiasis, and it is estimated that 50 million people in some 36 countries are at risk of contracting African sleeping sickness [Ann. Trop. Med. Parasitol.
- Leishmaniases are a group of human parasitic diseases caused by protozoa of the genus Leishmania and are manifested in three major forms: cutaneous, mucocutaneous, and visceral. Visceral leishmaniasis, due mainly to Leishmania donovani, is fatal if untreated. Current therapies for this and the other parasitic diseases suffer significant shortcomings.
- Primaquine is an 8-aminoquinoline and the drug of choice for the radical cure of relapsing malaria [Drugs, 39, 160(1990) D. M. Panisko et al. ibid 39, 337(1990) J. S Keystone] caused by Plasmodium vivax and P. ovale and is also being used as a prophylactic against all major forms of human malaria [Am. J. Trop. Med. Hyg. (supp), 49(3), Abrs. 417(1990) J. K. Baird et al.]. This drug was found to have significant sporontocidal and gametocytocidal [Military Med., 134, 802-819(1969) K. H.
- the present invention relates to new and more active and/or less toxic compositions for the treatment of parasitic and opportunistic infections and diseases.
- These compositions comprise enantiomerically pure stereoisomers or mixtures of stereoisomers of 8-aminoquinoline analogs with the best activity and toxicity profile for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, malaria, trypanosomaiasis, and leishmaniasis in mammals.
- PCP Pneumocystis carinii pneumonia
- toxoplasmosis malaria
- trypanosomaiasis trypanosomaiasis
- leishmaniasis in mammals.
- the present invention relates to improvements in the chemotherapy of parasitic diseases through the separation of racemic 8-aminoquinoline compounds with desirable activity and toxicity profiles into pure enantiomers and the selection of the pure enantiomer with improved therapeutic and/or toxicity profile for enhanced treatment.
- the present invention comprises the use of enantiomerically pure 8-aminoquinolines other than primaquine for the enhanced treatment of parasitic infections and diseases including opportunistic parasitic infections and diseases.
- the invention also encompasses new aminoquinolines which have not previously been described.
- mice Mice surviving 60 days/Mice infected and treated Oral Dose, mg/kg,day; (Total dose, mg/kg) 1 (3) 4 (12) 16 (48) 64 (192) Compound # 0/7 0/7 1/7 3/7 Primaquine DN 3-27-1 7/7 7/7 7/7 7/7 1 4/7 7/7 7/7 1/7 2 6/7 7/7 7/7 5/7 3 2/7 7/7 7/7 6/7 4 7/7 7/7 4/7 0/7 WR-225,448 7/7 7/7 7/7 4/7 WR-238,605 0/7 1/7 7/7 1/7 Control 0/7
- DN3-27-1 is the most active and also the least toxic (no mice showed toxicity at the highest dose tested). This compound had also shown excellent activity by the subcutaneous route of administration [J. Med. Chem., 25, 1094(1982) M. P. LaMontagne et al.] (See Table 2), and a higher radical curative activity (Table 3) than primaquine [J. Med. Chem., 25, 1094(1982) M. P. LaMontagne et al.]. TABLE 2 Suppressive Antimalarial Activity of DN3-27-1: Blood schizontocidal activity against P. berghei in mice (J. Med. Chem., 2 5, 1094(1982) M.P.
- mice were treated with a single dose of the compound administered subcutaneously 72 h after infection. Number of cures is the number of mice surviving, out of five, 60 days postinfection. TABLE 3 Radical Antimalarial Curative Activity of DN3-27-1 against P. cynomolgi in rhesus monkey (J. Med. Chem., 2 5, 1094(1982) M.P. LaMontagne et al.): Orally multiple dose Monkeys infected and treated/cured Dose, mg/kg/day; (X7) Compound 0.1 0.316 1.0 DN3-27-1 0/3 1/2 3/3 Primaquine 0/2 1/2
- DN3-27-1 was evaluated for in vitro (Table 6) and in vivo (Table 7) antipneumocystis activity by the methods described hereinbelow. TABLE 6 In vitro antipneumocystis activity of DN3-27-1 Concentration ( ⁇ g/ml) % of control on day 7 10 3.2 1.0 40.5 0.1 76.7
- Enantiomers of primaquine were prepared and evaluated for their antipneumocystis activity. One enantiomer showed significantly greater activity than the other. TABLE 8 Oral anti- Pneumocystis carinii activity of primaquine in mice Number of animals with organism after treatment/Number of animals treated Compound Dose: mg/kg/day (x21) Giesma Stain Primaquine 10 5/10 (+) Enantiomer 10 1/10 ( ⁇ ) Enantiomer 10 10/10 Primaquine 5 10/10 (+) Enantiomer 5 7/10 ( ⁇ ) Enantiomer 5 10/10 Primaquine 2 10/10 (+) Enantiomer 2 10/10 ( ⁇ ) Enantiomer 2 10/10 TMP/SMX 50/250 1/10 Control 10/10
- DN3-27-1 has shown in vitro activity at very low concentrations against a variety of strains of Leishmania. TABLE 9 In Vitro Anti-Leishmania Activity of DN-3-27-1 Compound Organism Giemsa Counts None (Control) L. mexicana amazonensis 15.10 ⁇ 2.18 DN-3-27-1 10 ⁇ g/mL L. mexicana amazonensis 1.30 ⁇ 0.38 None (Control) L. donovani Chagasi PP75 6.35 ⁇ 068 DN-3-27-1 50 ng/mL L. donovani Chagasi PP75 0.95 ⁇ 0.27 DN-3-27-1 150 ng/mL L.
- the present invention hence, relates to the finding that a particular enantiomer of DN3-27-1 as well as particular enantiomers of substituted 8-aminoquinolines other than primaquine have significantly greater activity and/or less toxicity than the other enantiomer or the diastereomeric mixture in the treatment of parasitic and opportunistic infections and diseases.
- the present invention relates to new 8-aminoquinoline compositions and to the pure active enantiomers of 8-aminoquinolines other than primaquine and also to the use of these compositions as pharmaceuticals when combined with an acceptable pharmaceutical carrier in the treatment of parasitic and opportunistic infections and diseases.
- the present compositions can also be used as prophylactics for the prevention of parasitic or opportunistic infections or diseases.
- compositions of the instant invention including the pure enantiomers and novel 8-amino-quinolines includes, for example, antimalarial activity and antipneumocystic activity.
- compositions would be employed using that amount of enantiomerically pure compound which is an effective amount to obtain the desired antiparasitic or antiinfective activity.
- the present invention it is proposed to utilize compounds (+) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline (X) and ( ⁇ ) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline(Y) to treat Pneumocystis carinii pneumonia (PCP), toxoplasmosis, malaria, trypanosomiasis, or leishmaniasis.
- PCP Pneumocystis carinii pneumonia
- toxoplasmosis malaria
- trypanosomiasis or leishmaniasis
- Administration of the compounds of the invention may be parenteral oral intravenous, intramuscular, subcutaneous, intrapleural, intrathecal, intraperitoneal, aerosol or transdermal administration to achieve the desirable antiparasitic effect.
- These drugs may be administered as the free base form or in the form of a pharmaceutically acceptable acid addition salt wherein the acid addition salt may be either organic or inorganic in nature.
- Suitable inorganic acids for salt formation include but are not restricted to: phosphoric acid, hydrochloric acid, sulfuric acid, or hydrobromic acid.
- Suitable organic acids for the formation of salts may include but are not restricted to: succinic acid, citric acid, fumaric acid, isothionic acid or pamoic acid.
- the compounds of the invention When administered orally, the compounds of the invention may be in the form of tablets (single or multilayer, coated or uncoated) capsules or dragees. These oral formulations may be admixed with a solid excipient such as lactose, sucrose, starch, microcrystalline cellulose, magnesium sterate, or talc.
- a solid excipient such as lactose, sucrose, starch, microcrystalline cellulose, magnesium sterate, or talc.
- an aqueous solution or an oleaginous formulation of the agent may be employed.
- Aqueous solutions can be prepared in water, physiological saline, Ringer's solution, or the like, either with or without buffers.
- Oleaginous formulation may be made in natural oils (as, peanut oil or olive oil), or in benzyl benzoate, for example.
- the actual dosage amount administered can be determined by physical and physiological factors such as body weight, severity of condition, and idiopathy of the patient. With these considerations in mind, the dosage of an active 8-amino-quinoline for a particular subject and/or course of treatment can readily be determined.
- Both enantiomers X and Y mentioned, hereinabove, are to be included as preferred antiparasitic agents and advantage may accrue in the choice of one or the other of these.
- the preferred salts include succinate, phosphate, and citrate.
- the present invention relates to compounds of the formula:
- R is an alkylene group which is
- n is 3 or 4, wherein R 1 and R 2 are methyl or ethyl; wherein R 3 is hydrogen or isopropyl, wherein R 4 , R 5 and R 6 are hydrogen, chloro, bromo, fluoro, trifluoromethyl or methoxy groups, and wherein the compound is a free amine or a pharmaceutically acceptable acid amine salt.
- Preferred compounds within this class of compounds include:
- the present invention further relates to enantiomerically pure 8-aminoquinoline compounds such as DN3-27-1, WR-238,605, WR-225-448 and compound 4 shown on hereinabove.
- the enantiomeric compounds encompassed by the invention in each instance is that enantiomer which provides significantly greater activity than the other enantiomer and/or lesser toxicity than the other. Enantiomeric separation is within the skill in the art.
- a preferred method in the instant invention is derivatization with (R)(+)- ⁇ -methylbenzyl isocyanate and separation using C-18 reverse-phase column chromatography or fractional crystallization.
- Another preferred method in the instant invention is derivatization with S( ⁇ )- ⁇ -methylbenzyl isocyanate and separation using C-18 reverse-phase column chromatography of fractional crystallization.
- the resulting precipitate was separated by filtration and dried.
- the solid was dissolved in chloroform and mixed with activated charcoal and filtered through a celite bed.
- the celite bed was washed with chloroform and the filtrate was concentrated to 400 ml under vacuum and diluted with methanol until a turbidity appeared and left overnight.
- the crystalline product formed was separated by decantation and crystallized from chloroform to give 8 g of pure product, 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-nitroquinoline.
- Drugs were mixed in 0.5% hydroxycellulose 0.1% Tween 80 and administered orally b.i.d. on days 3, 4 and 5 postinfection.
- CD-1 male or female mice 5 weeks of age, were infected with 5 ⁇ 10 4 parasitized erythrocytes of Plasmodium berghei KBG-173 mm strain. Blood films were taken on day +6 and weekly thereafter until day +60. Parasitemias were calculated and SD90 value (dose suppressing 90% of the parasites in treated groups compared with the infected non-treated controls) on day +6 postinfection. Mortality data was tabulated for 60 days at which time all mice surviving that were blood film negative were considered cured.
- Efficacy of the drug is determined by the number of cures at the end of a 30 day period and the increase in mean survival time over the control ( ⁇ MST).
- the effect of the test drugs also could be determined by the reduction of the parasitemia (percentage of the red blood cells detected with the parasites) over the untreated control on day 6, one day after the treatment is completed. Both these methods yield virtually identical results. If the dose of test compounds are inadequate, after initial clearance, residual parasites will multiply and relapses will occur within thirty days.
- the blood schizontocidal activities (suppressive antimalarial) of X, Y, and racemate against P. berghei in mice are shown in Table 11.
- Drugs were mixed in 0.5% hydroxycellulose 0.1% Tween 80 and administered orally b.i.d. either on day 5, 4, 3, 2, or 1 prior to the infection or 1 or 2 days postinfection.
- CD-I male or female mice 5 weeks of age, were infected with 5 ⁇ 10 4 parasitized erythrocytes ot Plasmodium berghei KBG-173 mm strain. Blood films were taken on day +6 and weekly thereafter until day+30. Mortality data was tabulated for 30 days at which time all mice surviving that were blood film negative were considered cured.
- the prophylactic activities of X, Y, and racemate against P. berghei in mice are shown in Table 5.
- This test is designed to evaluate the effectiveness of test compounds for the treatment of Pneumocystis carinii pneumonia in immunosuppressed animals.
- Virus and Pneumocystis carinii-free mice were utilized. Animals received standard chow containing 23% protein and also received tetracycline (0.5 mg/mL) in the drinking water.
- mice were immunosuppressed with dexamethasone at 1.2 mg/kg or 4.8 mg/kg in drinking water and 7-14 day animals were transtracheally inoculated with P. carinii and were continued on immunosuppressive agents.
- animals were anesthetized intramuscularly with 0.02 mL of a ketamine cocktail containing ketamine hydrochloride (80.0 mg/mL), atropine (0.38 mg/mL), and acepromazine (1.76 mg/mL), and an incision of approximately 1 cm was made over trachea, which was then exposed by blunt dissection.
- a group of untreated animals served as a control and a group of trimethoprim (TMP)/sulfamethoxazole (SMX)-treated (50/250 mg/kg/day) animals served as a positive treatment control.
- TMP trimethoprim
- SMX sulfamethoxazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
- [0001] This invention was supported by Public Health Service Grant #1 U01 AI35203 for the National Cooperative Drug Discovery Group.
- The present invention relates to new compositions useful in treating parasitic and opportunistic infections. Additionally, the present invention relates to the use of enantiomers of 8-aminoquinoline compounds for the treatment of Pneumocystis carinii, pneumonia (PCP), toxoplasmosis, malaria, trypanosomaiasis, and leishmaniasis in mammals and the prevention of PCP and malaria in mammals.
- Parasitic diseases are a major health problem in the world. Malaria, due to one of four Plasmodium species, is the most widespread parasitic disease, with a reported total of 100 million clinical cases that lead to more than 1 million deaths annually. Trypanosomiases are diseases caused by the protozoa of the genus Trypanosoma. Two major forms of this disease occur in man: African trypanosomiasis (sleeping sickness) and American trypanosomiasis (Chagas disease). Some 16-18 million people are infected with T. cruzi, the cause of American trypanosomiasis, and it is estimated that 50 million people in some 36 countries are at risk of contracting African sleeping sickness [Ann. Trop. Med. Parasitol. 85, 43 (1991) M. L. Ruiz et al.]. Leishmaniases are a group of human parasitic diseases caused by protozoa of the genus Leishmania and are manifested in three major forms: cutaneous, mucocutaneous, and visceral. Visceral leishmaniasis, due mainly to Leishmania donovani, is fatal if untreated. Current therapies for this and the other parasitic diseases suffer significant shortcomings.
- In addition to the significant morbidity and mortality associated with the parasitic infections, with the advent of AIDS epidemic, opportunistic parasitic diseases such as Pneumocystis carinii pneumonia, toxoplasmosis and cryptosporidiosis have become the leading cause of death among AIDS patients throughout the world. The non-availability of safe and efficacious drugs and drug resistance have hampered the effective treatment of all of these diseases.
- Primaquine is an 8-aminoquinoline and the drug of choice for the radical cure of relapsing malaria [Drugs, 39, 160(1990) D. M. Panisko et al. ibid 39, 337(1990) J. S Keystone] caused by Plasmodium vivax and P. ovale and is also being used as a prophylactic against all major forms of human malaria [Am. J. Trop. Med. Hyg. (supp), 49(3), Abrs. 417(1990) J. K. Baird et al.]. This drug was found to have significant sporontocidal and gametocytocidal [Military Med., 134, 802-819(1969) K. H. Rieckmann et al.] activity but very low activity against blood stage malaria parasites at therapeutic doses [Prog. Med. Chem., 28, 1(1991) E. A. Nodiff et al.]. Moreover, primaquine is reported to be active in animal models of other parasitic infections, including Trypanosomiasis [PQ Activity vs. Trypanosoma, J. Parasit., 74, 748 (1988) R. E. McCabe]. In addition to its activity against the parasitic infections, primaquine in combination with clindamycin has been successfully used for the treatment as well as prophylaxis of Pneumocystis carinii pneumonia in AIDS patients [South. Med. J., 83, 403(1990) R. Kay et al.; Lancet i, 1046(1989) E. Toma et al.; Clin. Infect. Dis., 14: 183(1992) G. S. Noskinm et al.]. This drug has also shown significant activity against other disease causing parasites such as Trypanosoma [J. Parasit., 74, 748(1988) R. E. McCabe] and Leishmanic [Am. J. Trop. Med. Hyg., 32, 753(1983) D. J. Berman et al.]. D. J. Berman et al.]. There are three reports on the use of primaquine for the treatment of Trypanosoma cruzi infection in humans [J. Parasit., 74, 748(1988) R. E. McCabe]. The major limitation of primaquine and other 8-aminoquinoline antimalarials is that they cause methemoglobinemia [N. Engl. J. Med., 279, 1127(1968) R. J. Cohen et al.] and hemolysis [Arch. Intern. Med. 109, 209(1962) A. R. Tarlov et al.] in individuals who suffer from glucose-6-phosphate dehydrogenase deficiency.
- Over the years, several attempts have been made to improve the therapeutic index of primaquine against malaria and Leishmania through modification of its chemical structure. Introduction of 4-methyl and 5-phenoxy [J. Med. Chem. 25, 1094(1982) M. P. LaMontagne et al.; ibid, 25, 1097(1982) E. A. Nodiff et al.] or alkoxy groups [J. Med. Chem. 30, 1193(1987) E. H. Chen et al.] have produced analogs with much superior tissue and blood schizonticidal activity. However, toxicity studies have shown that these analogs also have a greater potential of producing methemoglobin [Fundam. Appl. Toxicol., 10, 270(1988) J. Anders et al.]. Recently, LaMontagne [J. Med. Chem., 32, 1728(1989) M. P. LaMontagne et al.] has reported that introduction of a methoxyl at position 2 of the quinoline ring reduces the toxicity of some of these compounds, especially induction of methemoglobin, without losing activity. Based on these results, the US Army selected an 8-aminoquinoline derivative, WR-238,605, as a potential replacement for primaquine for the treatment of relapsing malaria [Pharm. Res., 8, 1505(1991) R. P. Brueckner at el.].
- Similarly, the US Army had selected WR-6026, a 4-methylprimaquine analog, as a potential drug for the treatment of leishmaniasis [Xenobiotica, 20, 31(1990) L. A. Shipley et al.]. Since the compound WR-6026 was selected as the potential candidate for the treatment of leishmaniasis in 1978 [Am. J. Trop. Med. Hyg., 27, 751(1978) K. E. Kinnamon et al.], a large number of 5-phenoxy or 5-alkoxy-4-methylprimaquine analogs have been synthesized. Some of these analogs have shown higher antileishmanial activity than WR-6026 in an in vitro assay [Am. J. Trop. Med. Hyg., 32, 753(1983) D. J. Berman et al.].
- After the first report [Antimicrob. Ag. Chemotherap., 32, 807(1988) S. F. Queener et al.] of antipneumocystis activity of primaquine in combination with clindamycin, several other 8-aminoquinolines were evaluated for antipneumocystic activity [Antimicrob. Ag. Chemotherap., 34: 277(1991) M. S. Bartlett et al.; ibid., 37, 2166(1993) S. Queener] and some of them, even when used alone, were found to be superior to the primaquine/clindamycin combination.
- The effect of isomerism on biological activity and toxicity is well documented. However, this phenomenon has received little attention in the case of the 8-aminoquinolines. Schmidt et al [Antimicrob. Ag. Chemotherap., 12, 51 (1977) L. H. Schmidt] examined the relative curative and toxic activities of primaquine and its d- and l-_isomers in mice and rhesus monkeys. They confirmed an earlier report that d-primaquine was approximately 4 times as toxic as the l-form in mice but that the opposite is true in the rhesus monkey in which the l-form was 3 to 5 times as toxic as the d-primaquine and at least twice as toxic as, in which racemic primaquine. More importantly, all three forms of primaquine, the d- and l- and dl-, showed essentially identical curative properties against sporozoite induced P. cynomolgi infections. In studies on the metabolism of d- and l-isomers it was shown that the metabolic rates for the d- and l- isomers were different [J. Pharm. Sci., 77, 380(1988) J. K. Baker et al.]. Several other studies also have shown different activities and toxicities for d- and l-isomers [Biochem. Pharmacol., 37: 4605(1988) S. Agarwal et al.; FEBS Letts., 214, 291(1987) A. Brossi et al.]
- The present invention relates to new and more active and/or less toxic compositions for the treatment of parasitic and opportunistic infections and diseases. These compositions comprise enantiomerically pure stereoisomers or mixtures of stereoisomers of 8-aminoquinoline analogs with the best activity and toxicity profile for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, malaria, trypanosomaiasis, and leishmaniasis in mammals.
- The present invention relates to improvements in the chemotherapy of parasitic diseases through the separation of racemic 8-aminoquinoline compounds with desirable activity and toxicity profiles into pure enantiomers and the selection of the pure enantiomer with improved therapeutic and/or toxicity profile for enhanced treatment.
- A number of compounds of the 8-aminoquinoline class were synthesized and their anti-parasitic activities were evaluated by administration of the test compounds to mice orally, in multiple doses. Compounds with optimum therapeutic and toxicity profiles were chosen, separated into enantiomers and the activity profile of the each enantiomer was determined. Surprisingly it was observed that (−) enantiomer of DN3-27-1 possessed significantly greater activity than the (+) enantiomer in the mouse model of PCP. It is speculated that the active enantiomer is responsible for the observed activity of DN3-27-1 at minimum effective doses. Hence, the present invention comprises the use of enantiomerically pure 8-aminoquinolines other than primaquine for the enhanced treatment of parasitic infections and diseases including opportunistic parasitic infections and diseases. The invention also encompasses new aminoquinolines which have not previously been described.
- In the experimental investigation leading to the present invention, the applicants prepared and evaluated the antipneumocystic, antitoxoplasma, antimalarial (blood schozontocidal activity), antitrypanosomal, and antileishmanial activities of 8-aminoquinoline analogs, which included some compounds, in their racemate form, that were previously reported to be active against malaria [J. Med. Chem., 25, 1094(1982) M. P. LaMontagne et al.; ibid, 25, 1097(1982) E. A. Nodiff et al.; J. Med. Chem., 30, 1193(1987) E. H. Chen et al], and some novel analogs in their racemic form. Separation of the racemates provided enantiomerically pure isomers that were found to exhibit improved therapeutic and/or toxicity profiles.
-
- The blood schizonticidal activity of selected 8-aminoquinolines (Table I) was determined as described herein. Prophylactic efficacy of selected 8-aminoquinolines was determined as described herein.
TABLE I Antimalarial Activity of 8-aminoquinolines: Blood schizontocidal activity against P. bergheiin mice: Mice surviving 60 days/Mice infected and treated Oral Dose, mg/kg,day; (Total dose, mg/kg) 1 (3) 4 (12) 16 (48) 64 (192) Compound # 0/7 0/7 1/7 3/7 Primaquine DN 3-27-1 7/7 7/7 7/7 7/7 1 4/7 7/7 7/7 1/7 2 6/7 7/7 7/7 5/7 3 2/7 7/7 7/7 6/7 4 7/7 7/7 4/7 0/7 WR-225,448 7/7 7/7 7/7 4/7 WR-238,605 0/7 1/7 7/7 1/7 Control 0/7 - DN3-27-1, is the most active and also the least toxic (no mice showed toxicity at the highest dose tested). This compound had also shown excellent activity by the subcutaneous route of administration [J. Med. Chem., 25, 1094(1982) M. P. LaMontagne et al.] (See Table 2), and a higher radical curative activity (Table 3) than primaquine [J. Med. Chem., 25, 1094(1982) M. P. LaMontagne et al.].
TABLE 2 Suppressive Antimalarial Activity of DN3-27-1: Blood schizontocidal activity against P. bergheiin mice (J. Med. Chem., 2 5, 1094(1982) M.P. LaMontagne et al.) Subcutaneously as a single dose Mice infected and treated/Mice surviving 60 days Dose, mg/kg Compound 5 10 20 40 80 160 320 640 DN3-27-1 5/4 5/5 5/5 5/5 5/5 5/5 5/5 5/5 Control 0/5 - Mice were treated with a single dose of the compound administered subcutaneously 72 h after infection. Number of cures is the number of mice surviving, out of five, 60 days postinfection.
TABLE 3 Radical Antimalarial Curative Activity of DN3-27-1 against P. cynomolgiin rhesus monkey (J. Med. Chem., 2 5, 1094(1982) M.P. LaMontagne et al.): Orally multiple dose Monkeys infected and treated/cured Dose, mg/kg/day; (X7) Compound 0.1 0.316 1.0 DN3-27-1 0/3 1/2 3/3 Primaquine 0/2 1/2 - Primaquine has been effectively used as a prophylactic against malaria. Several compounds were tested for oral prophylactic activity. Mice treated with a single dose of 2 mg/kg of compound DN3-27-1 within the period of 2 days preinfection through 2 days post infection were completely protected from malaria (Table 4).
TABLE 4 Prophylactic Activity of DN3-27-1. Mice infected and Mice/treated surviving day 60 dose, mg/kg Day of Treatment 2 8 32 128 −3 0/5 5/5 5/5 5/5 −2 5/5 5/5 5/5 5/5 −1 5/5 5/5 5/5 5/5 1 5/5 5/5 5/5 5/5 2 5/5 5/5 5/5 5/5 -
TABLE 5 Prophylactic Anti-Malarial Activity of Enantiomers of DN3-27-1 (single dose of 2 mg/kg) Mice surviving day 60/Mice Compound Day of Treatment infected and treated DN3-27-1 −5 0/5 X Enantiomer −5 0/5 Y Enantiomer −5 0/5 DN3-27-1 −4 0/5 X Enantiomer −4 0/5 Y Enantiomer −4 0/5 DN3-27-1 −3 0/5 X Enantiomer −3 0/5 Y Enantiomer −3 0/5 DN3-27-1 −2 0/5 X Enantiomer −2 0/5 Y Enantiomer −2 1/5 DN3-27-1 2 2/5 X Enantiomer 2 0/5 Y Enantiomer 2 5/5 Controls 0/5 - Primaquine in combination with clindamycin is currently being used for the treatment and as prophylaxis of P. carinii pneumonia in AIDS patients [South. Med. J., 83, 403(1990) R. Kay et al., Lancet i, 1046(1989) E. Toma e al., Clin. Infect. Dis., 14: 183(1992) G. S. Noskinm et al.]. Some of the 8-aminoquinolines, especially those bearing a 4-methyl and 5-phenoxy or alkoxy groups have shown superior in vivo antipneumocystis activity in mice compared to primaquine even when tested alone [Antimicrob. Ag. Chemotherap., 34: 277(1991) M. S. Bartlett et al., ibid., 37, 2166(1993) S Queener]. DN3-27-1 was evaluated for in vitro (Table 6) and in vivo (Table 7) antipneumocystis activity by the methods described hereinbelow.
TABLE 6 In vitro antipneumocystis activity of DN3-27-1 Concentration (μg/ml) % of control on day 7 10 3.2 1.0 40.5 0.1 76.7 -
TABLE 7 Oral antipneumocystis activity of DN3-27-1 in mice. Number of animals with organism after treatment/Number of animals treated Compound Dose: mg/kg/day (x21) Giesma Stain Silver Stain DN3-27-1 1.2 1/10 1/10 TMP/SMX 50/250 1/10 1/10 Control 10/10 10/10 - Enantiomers of primaquine were prepared and evaluated for their antipneumocystis activity. One enantiomer showed significantly greater activity than the other.
TABLE 8 Oral anti- Pneumocystis cariniiactivity of primaquine in mice Number of animals with organism after treatment/Number of animals treated Compound Dose: mg/kg/day (x21) Giesma Stain Primaquine 10 5/10 (+) Enantiomer 10 1/10 (−) Enantiomer 10 10/10 Primaquine 5 10/10 (+) Enantiomer 5 7/10 (−) Enantiomer 5 10/10 Primaquine 2 10/10 (+) Enantiomer 2 10/10 (−) Enantiomer 2 10/10 TMP/SMX 50/250 1/10 Control 10/10 - DN3-27-1 has shown in vitro activity at very low concentrations against a variety of strains of Leishmania.
TABLE 9 In Vitro Anti-Leishmania Activity of DN-3-27-1 Compound Organism Giemsa Counts None (Control) L. mexicana amazonensis 15.10 ± 2.18 DN-3-27-1 10 μg/mL L. mexicana amazonensis 1.30 ± 0.38 None (Control) L. donovaniChagasi PP75 6.35 ± 068 DN-3-27-1 50 ng/mL L. donovaniChagasi PP75 0.95 ± 0.27 DN-3-27-1 150 ng/mL L. donovaniChagasi PP75 0.10 ± 0.03 DN-3-27-1 450 ng/mL L. donovaniChagasi PP75 0.00 ± 0.00 Atovaquone 1350/ng/mL L. donovaniChagasi PP75 5.05 ± 0.21 - Preliminary evaluation of DN3-27-1 in vitro against Toxoplasma gondii showed that it had an activity at around 50 μM.
- Compounds were tested vs. trypanosome isolates grown as blood forms in HMI-18 (Hirumi H., Hirumi, K. 1989. Continuous Cuitivation of Trypanosoma brucei bloodstream forms in a medium containing a low concentration of serum portein without feeder cell layers. J. Parasitol. 75:985-989) containing 20% horse serum. Hemocytometer counts or Coulter counts were made daily and IC50 values determined after 48 h.
IC50(μM) EATRO KETRI Lab 110 243As103 243 269 X 8.3 36 34 37.0 Y 13.5 17.5 11 27.0 DN3-27-1 9.4 10.9 29 5.0 - The present invention, hence, relates to the finding that a particular enantiomer of DN3-27-1 as well as particular enantiomers of substituted 8-aminoquinolines other than primaquine have significantly greater activity and/or less toxicity than the other enantiomer or the diastereomeric mixture in the treatment of parasitic and opportunistic infections and diseases. The present invention relates to new 8-aminoquinoline compositions and to the pure active enantiomers of 8-aminoquinolines other than primaquine and also to the use of these compositions as pharmaceuticals when combined with an acceptable pharmaceutical carrier in the treatment of parasitic and opportunistic infections and diseases. The present compositions can also be used as prophylactics for the prevention of parasitic or opportunistic infections or diseases.
- The antiparasitic activity of the compositions of the instant invention including the pure enantiomers and novel 8-amino-quinolines includes, for example, antimalarial activity and antipneumocystic activity. In each instance, the compositions would be employed using that amount of enantiomerically pure compound which is an effective amount to obtain the desired antiparasitic or antiinfective activity.
- According to a specific embodiment the present invention, it is proposed to utilize compounds (+) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline (X) and (−) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline(Y) to treat Pneumocystis carinii pneumonia (PCP), toxoplasmosis, malaria, trypanosomiasis, or leishmaniasis.
- Administration of the compounds of the invention may be parenteral oral intravenous, intramuscular, subcutaneous, intrapleural, intrathecal, intraperitoneal, aerosol or transdermal administration to achieve the desirable antiparasitic effect. These drugs may be administered as the free base form or in the form of a pharmaceutically acceptable acid addition salt wherein the acid addition salt may be either organic or inorganic in nature. Suitable inorganic acids for salt formation include but are not restricted to: phosphoric acid, hydrochloric acid, sulfuric acid, or hydrobromic acid. Suitable organic acids for the formation of salts may include but are not restricted to: succinic acid, citric acid, fumaric acid, isothionic acid or pamoic acid. When administered orally, the compounds of the invention may be in the form of tablets (single or multilayer, coated or uncoated) capsules or dragees. These oral formulations may be admixed with a solid excipient such as lactose, sucrose, starch, microcrystalline cellulose, magnesium sterate, or talc. When parenteral administration may be indicated, an aqueous solution or an oleaginous formulation of the agent may be employed. Aqueous solutions can be prepared in water, physiological saline, Ringer's solution, or the like, either with or without buffers. Oleaginous formulation may be made in natural oils (as, peanut oil or olive oil), or in benzyl benzoate, for example.
- The actual dosage amount administered can be determined by physical and physiological factors such as body weight, severity of condition, and idiopathy of the patient. With these considerations in mind, the dosage of an active 8-amino-quinoline for a particular subject and/or course of treatment can readily be determined.
- Both enantiomers X and Y mentioned, hereinabove, are to be included as preferred antiparasitic agents and advantage may accrue in the choice of one or the other of these. The preferred salts include succinate, phosphate, and citrate.
-
-
- wherein n is 3 or 4, wherein R1 and R2 are methyl or ethyl; wherein R3 is hydrogen or isopropyl, wherein R4, R5 and R6 are hydrogen, chloro, bromo, fluoro, trifluoromethyl or methoxy groups, and wherein the compound is a free amine or a pharmaceutically acceptable acid amine salt.
- Preferred compounds within this class of compounds include:
- 1. 8-((4-Amino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)-quinoline
- 2. 8-((4-Amino-1-pentyl)amino)-6-methoxy-4-methyl-5-(2,4,5 trichlorophenoxy)-quinoline
- 3. 8-((5-Amino-1-hexyl)amino)-6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)-quinoline
- 4. 8-((4-Amino-1-ethylbutyl)amino)-6-methoxy-4-methyl-5-(2,4,5-trichlorophenoxy)-quinoline
- 5. 8-((4-Isopropylamino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(2,4,6;tritrifluoromethylphenoxy)-quinoline
- 6. 8-((4-Amino-1-methylbutyl)amino)-6-methoxy-5-(2,4,6-trichlorophenoxy)-4-methyl-quinoline
- 7. 8-((4-Amino-1-methylbutyl)amino)-2,4,5-trifluorophenoxy)-6-methoxy-4-methylquinoline
- 8. 8-((4-Amino-1-methylbutyl)amino)-5-(2,4,5-tritrifluoromethylphenoxy)-6-methoxy-4-methylquinoline
- The present invention further relates to enantiomerically pure 8-aminoquinoline compounds such as DN3-27-1, WR-238,605, WR-225-448 and compound 4 shown on hereinabove. The enantiomeric compounds encompassed by the invention in each instance is that enantiomer which provides significantly greater activity than the other enantiomer and/or lesser toxicity than the other. Enantiomeric separation is within the skill in the art. A preferred method in the instant invention is derivatization with (R)(+)-α-methylbenzyl isocyanate and separation using C-18 reverse-phase column chromatography or fractional crystallization. Another preferred method in the instant invention is derivatization with S(−)-α-methylbenzyl isocyanate and separation using C-18 reverse-phase column chromatography of fractional crystallization.
-
- In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that the same is intended only as illustrative and in no way limitative.
- In the examples below as well as elsewhere in this specification, all temperatures are in degrees Celsius (° C.).
- Reactions for the preparation of DN3-27-1 and compounds X and Y
- 2-Nitro-4-methoxy-5-(3,4-dichlorophenoxy)acetanilide
- A solution of 50 g of 3,4-dichlorophenol (0.307 mole) and 20.2 g of 85% KOH (0.307 mole) in 250 ml of dry DMF was added into a 67.6 g solution of 2-nitro-4-methoxy-5chloroacetanilide (0.275 mole) in 250 ml of DMF at 120° C. with stirring under nitrogen atmosphere. After the addition was complete the reaction mixture was stirred for further 5 hours at this temperature. The reaction mixture was poured into cold water with stirring. The resulting precipitate was separated by filtration and was crystallized from chloroform/methanol to yield 84 g of the product, 2-nitro-4-methoxy-5-(3,4-dichlorophenoxy)acetanilide
- 2-Nitro-4-methoxy-5-(3,4-dichlorophenoxy)aniline hydrochloride
- A mixture of 84 g of 2-nitro-4-methoxy-5-(3,4-dichlorophenoxy)acetanilide (0.22 mole) and 100 ml of concentrated HCl in 11 of ethanol was refluxed for 5 hours. The solvent was removed under vacuum and the product obtained was used in the next reaction without further purification.
- 5-(3,4-Dichlorophenoxy)-6-methoxy-4-methyl-8-nitroquinoline
- A mixture of 83 g of 2-nitro-4-methoxy-5-(3,4-dichlorophenoxy)aniline hydrochloride (0.22 mole) polyphosphoric acid in 250 ml of 85% phosphoric acid was heated in a nitrogen atmosphere at 110-120° C. and 32.17 g of methyl vinyl ketone (0.46 mole) was added dropwise under vigorous stirring. After the addition was complete, the mixture was stirred and maintained at 110-120° C. for a further 4 hours. An additional 14 g of methyl vinyl ketone (0.2 mole) was added and the mixture was heated for a further 4 hours. The reaction mixture was poured into ice cold sodium hydroxide solution (pH 10-12) and left over night. The resulting precipitate was separated by filtration and dried. The solid was dissolved in chloroform and mixed with activated charcoal and filtered through a celite bed. The celite bed was washed with chloroform and the filtrate was concentrated to 400 ml under vacuum and diluted with methanol until a turbidity appeared and left overnight. The crystalline product formed was separated by decantation and crystallized from chloroform to give 8 g of pure product, 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-nitroquinoline. The combined filtrates were evaporated to dryness and the residue was chromatographed over silica gel with 30% chloroform in hexane to yield a fraction from which the product which was crystallized (chloroform/methanol) to give 13 g of product.
- 8-Amino-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinoline
- To a mixture of 13 g of 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-nitroquinoline and 800 mg of 10% Pd on carbon in 500 ml of ethanol, was added 20 ml of 98% hydrazene hydrate portionwise with stirring. After the addition was complete, the reaction mixture was refluxed for 6 hours. The reaction mixture was filtered while hot and evaporated. The residue was partitioned between water and ethyl acetate, the organic layer was washed with water, dried and evaporated to give 12.4 g of crystalline product which was used in next reaction without further purification.
- 5-(3,4-dichlorophenoxy)-6-methoxy-1methyl-8-[(4-phthalimido-1-methylbutyl)amino] quinoline
- A mixture of 12.4 g of 8-amino-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinoline (36 mM) and 11.6 g of 4-oxo-1-phthalimidopentane (50 mM), in glacial acetic acid was stirred for 15 min under nitrogen and 2.6 g of sodium borohydride (70 mM) was added portionwise maintaining the temperature 25-35° C. After the addition, the reaction mixture was stirred for 30 min and then poured into ice cold solution of concentrated sodium hydroxide. The resulting precipitate was filtered and chromatographed over silica gel. Elution with hexanes:ethyl acetate 90:10 yielded the expected product of 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-[(4-phthalimido-1-methylbutyl)amino]quino line which was crystallized from ether to give 12.4 g (22 mM) of yellow crystalline product.
- 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinoline.
- A mixture of 12.2 g of 5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-8-[(4-phthalimido-1methylbutyl)amino]quinoline (21.6 mM) and 4 ml of 98% hydrazene hydrate in 500 ml of ethanol was refluxed 5 hours. The reaction mixture was evaporated under vacuum and the residue was partitioned between 400 ml of 10% potassium hydroxide and 400 ml of ethyl acetate. The organic layer was washed twice with 300 ml of 10% potassium hydroxide then four times with water, dried with anhydrous sodium sulfate and evaporated. The residue was used in the next reaction with out further purification.
- 8-[{4-(N(R)-1-phenylethylcarbamoyl)-1-methylbutyl}amino]-5-(3,4-dichlorophenoxy)-6methoxy-4-methyl-quinoline
- To a stirred solution of 8 g (18.4 mM) of 8-[(4-amino-1-methylbutyl)amino]-5-(3,4dichlorophenoxy)-6-methoxy-4-methyl-quinoline in toluene at 10° C., 2.98 g (20.3 mM )of (R)(+)-α-methylbenzyl isocyanate was added dropwise. The mixture was stirred for 30 mins and then the solvent was evaporated in vacuum and the residue was boiled in 200 ml of ethyl acetate and filtered. The ethyl acetate in soluble fraction was crystallized twice from ethyl acetate to give one diastereoisomer (I) in pure form 1.2 g.
- Ethyl acetate soluble fraction was recrystallized four times from methanol to give other diastereoisomer (I) in pure form (420 mg).
- (−)-8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinoline succinate (Y)
- A mixture of 800 mg of diastereomer I of 8-[{4-(N(R)-1-phenylethylcabamoyl)-1-methylbutyl} amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline and 8 gm of 85% potassium hydroxide in 80 ml of n-butanol was refluxed under nitrogen for 30 hours. The solvent was evaporated under vacuum and the residue was partitioned between ethyl acetate and water. The ethyl acetate layer was separated and the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layers were washed four times with water, dried over anhydrous sodium sulfate and evaporated. The gum obtained was chromatographed over basic alumina and elusion with ethyl acetate:methanol yielded 462 mg of 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy4-methylquinoline (1.06 mM). This was dissolved in 10 ml of ethanol containing 126 mg of succinic acid, diluted with 30 ml of diethyl ether and left overnight at 4° C. The resulting solid was separated by filtration to yield 373 mg of (−) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline succinate.
- (+) 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylquinoline succinate (X)
- A mixture of 285 mg of diastereomer II of 8-[{4-(N(R)-1-phenylethylcabamoyl)-1-methylbuty} amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline and 3 gm of 85% potassium hydroxide in 30 ml of n-butanol was refluxed under nitrogen for 30 hours. The solvent was evaporated under vacuum and the residue was partitioned between ethyl acetate and water. The ethyl acetate layer was separated and the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layers were washed four times with water dried over anhydrous sodium sulfate and evaporated. The gum obtained was chromatographed over basic alumina and elusion with ethyl acetate:methanol yielded 157 mg (0.36 mM) of 8-[(4-amino-1-methylbutyl)amino]-5-(3,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline. This was dissolved in 10 ml of ethanol containing 43 mg (0.36 mM) of succinic acid, diluted with 30 ml of diethyl ether and left overnight at 4° C. The resulting solid was separated by filtration to give 158 mg of (+) 8-[(4-amino-1-methylbutyl)amino]-5(3 ,4-dichlorophenoxy)-6-methoxy-4-methyl-quinoline succinate. Diastereomers obtained after the derivatization with (R)(+)-α-methylbenzyl isocyanate were also separated using C-18 reverse-phase column chromatography. This HPLC analysis method and proton NMR spectroscopy were used to determine the purity of the diastereomers.
- HPLC Analysis. Instrumentation consisted of a Waters LC Module I Multisolvent Delivery System, Waters 715 autoinjector, Waters pump 600, Waters UV detector 486 operating at 254 nm (Millipore Corporation, Waters Chromatography Division, Milford, Mass.) and a computer (NEC power mate 386/33i, Millennium 2000) for control of the analytical system, data collection and processing.
- Chromatography was carried out using Waters Resolve® (5μ spherical, 3.9×30 mm) C- 18 reverse-phase column and acetonitrile:tetrahydrofuran:85% lactic acid (76.5:13.5:10) mobile phase at a flow rate 2 ml./min. Compounds were detected using an UV detector operating at 254 nm.
- (+) and (−) Primaquine
- Primaquine was purchased from Aldrich Chemical Co. (Milwaukee, Wis.) and separated into (+) and (−) enantiomers using the procedure described by Carroll et al.[J. Med Chem., 21, 326 (1978), F. I. Carroll et al.].
- Blood Schizontocidal Test (Trophozoite-Induced Plasmodium berghei Infection in mice University of Miami, Test System: Thompson Test
- Drugs were mixed in 0.5% hydroxycellulose 0.1% Tween 80 and administered orally b.i.d. on days 3, 4 and 5 postinfection. CD-1 male or female mice, 5 weeks of age, were infected with 5×104 parasitized erythrocytes of Plasmodium berghei KBG-173 mm strain. Blood films were taken on day +6 and weekly thereafter until day +60. Parasitemias were calculated and SD90 value (dose suppressing 90% of the parasites in treated groups compared with the infected non-treated controls) on day +6 postinfection. Mortality data was tabulated for 60 days at which time all mice surviving that were blood film negative were considered cured.
- Compounds X and Y were tested at three dose levels, 4, 1, and 0.25 mg/kg body weight per day. The activity of these compounds were compared with the untreated control and “racemate” which is a mixture of equal amount of each enantiomer X and Y. In untreated controls, death occurs within 8-9 days. Compounds which are effective against Plasmodium berghei infection increase the mean survival time of the infected animals when compared with the untreated controls. Mice that survive after thirty days and are free of parasites in blood are considered cured.
- Efficacy of the drug is determined by the number of cures at the end of a 30 day period and the increase in mean survival time over the control (ΔMST). The effect of the test drugs also could be determined by the reduction of the parasitemia (percentage of the red blood cells detected with the parasites) over the untreated control on day 6, one day after the treatment is completed. Both these methods yield virtually identical results. If the dose of test compounds are inadequate, after initial clearance, residual parasites will multiply and relapses will occur within thirty days. The blood schizontocidal activities (suppressive antimalarial) of X, Y, and racemate against P. berghei in mice are shown in Table 11.
- Prophylactic Test
- Drugs were mixed in 0.5% hydroxycellulose 0.1% Tween 80 and administered orally b.i.d. either on day 5, 4, 3, 2, or 1 prior to the infection or 1 or 2 days postinfection. CD-I male or female mice, 5 weeks of age, were infected with 5×104 parasitized erythrocytes ot Plasmodium berghei KBG-173 mm strain. Blood films were taken on day +6 and weekly thereafter until day+30. Mortality data was tabulated for 30 days at which time all mice surviving that were blood film negative were considered cured. The prophylactic activities of X, Y, and racemate against P. berghei in mice are shown in Table 5.
- Anti-Pneumocystis carinii Test (Induced Pneumocystis carinii Infection in Mice)
- This test is designed to evaluate the effectiveness of test compounds for the treatment of Pneumocystis carinii pneumonia in immunosuppressed animals.
- Virus and Pneumocystis carinii-free mice were utilized. Animals received standard chow containing 23% protein and also received tetracycline (0.5 mg/mL) in the drinking water.
- Animals were immunosuppressed with dexamethasone at 1.2 mg/kg or 4.8 mg/kg in drinking water and 7-14 day animals were transtracheally inoculated with P. carinii and were continued on immunosuppressive agents. For transtracheal inoculation, animals were anesthetized intramuscularly with 0.02 mL of a ketamine cocktail containing ketamine hydrochloride (80.0 mg/mL), atropine (0.38 mg/mL), and acepromazine (1.76 mg/mL), and an incision of approximately 1 cm was made over trachea, which was then exposed by blunt dissection. The inoculum of 106 organisms in 0.05 mL and 0.4 mL of air were injected sequentially. The wound was closed with a single clip. The animals were continued on immunosuppressive agents. At 3 weeks post inoculation, treatment was begun and continued for three weeks. Compounds X and Y were tested at 4 dose levels, 5, 1, 0.5 and 0.25 milligram per kilogram body weight per day. ARacemate@ which is a mixture of equal amount of each enantiomer X and Y was tested at dose levels 1.3 and 0.25 mg/kg/day. A group of untreated animals served as a control and a group of trimethoprim (TMP)/sulfamethoxazole (SMX)-treated (50/250 mg/kg/day) animals served as a positive treatment control. At the end of three weeks of therapy, animals were anesthetized and exsanguinated by cardiac puncture. Lungs were removed and representative portions were used to make impression smears. Four impression smears, fixed in methanol, were evaluated for the presence of P. carinii by staining with Giemsa and modified methanamine silver nitrate. Slides were blinded and reviewed microscopically by three examiners who scored them on the following basis: More than 100 organism per x1,000 field, 5+; 11-100 organisms per field 4+; 1-10 per field 3+; 2-9 in ten field 2+; 1 in 10 or more fields 1+; no organism in 50 fields 0. Means of these scores were separately determined for the Giemsa-stained and silver-stained impression smears. Giemsa stains reveal living trophozoite forms and cyst forms. Silver stains reveal both living and dead cyst forms. For this reason Giemsa stains provide more reliable results and silver stains data were used to confirm the conclusions. The anti-Pneumocystis carinii pneumonia activity of X,Y, and racemate against Pneumocystis in mice is shown in Table 12.
-
TABLE 11 Suppressive Antimalarial Activity of X, Y and Racemate Against P. berghei in mice mg/kg/ mg/kg ΔMST Mice Alive Parasitemia Compound day Total days Day 26 Day 6 X 4 12 11 0/5 1.1 1 3 6 0/5 27.4 0.25 0.75 0 0/5 28.2 Y 4 12 5/5 0.0 1 3 13.6 4/5 0.0 0.25 0.75 11.6 0/0 0.2 Racemate 1 3 10.2 0/5 0.1 0.25 0.75 11.6 0/5 4.8 Control 0 0 0 0/5 31.8 -
TABLE 12 Oral Anti-Pneumocystis carinii activity of X, Y and racemate in mice Dose: mg/kg/ Giemsa Stain Silver stain Compound day (x21) I/T Score I/T Score X 5 0/10 0.0 0/10 0.0 Y 5 0/10 0.0 0/10 0.0 Racemate 1.3 0/10 0.0 0/10 0.0 X 1 0/10 0.0 0/10 0.0 Y 1 0/10 0.0 0/10 0.0 X 0.5 2/10 0.20 ± 0.10 2/10 0.1 ± 0.1 Y 0.5 X 0.25 4/10 0.55 ± 0.16 9/10 1.15 ± 0.16 Y 0.25 0/10 0.0 0/10 0.0 Racemate 0.25 2/10 TMP/SMX 50/250 1/10 0/03 ± 0.02 0/10 0.0 Control 10/10 4.43 ± 0.12 10/10 3.80 ± 0.08 - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described can be used in the practice of testing of the present invention, the preferred methods and materials are now described. All publications and patent documents referenced in this application are incorporated herein by reference in their entirety as though each and every publication and patent document was specifically incorporated herein by reference in its entirety.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and the various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
Claims (29)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/155,509 US6376511B2 (en) | 1996-03-29 | 1997-03-28 | 8-aminoquinolines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1429296P | 1996-03-29 | 1996-03-29 | |
US60014292 | 1996-03-29 | ||
US09/155,509 US6376511B2 (en) | 1996-03-29 | 1997-03-28 | 8-aminoquinolines |
PCT/US1997/005160 WO1997036590A1 (en) | 1996-03-29 | 1997-03-28 | 8-aminoquinolines |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010007031A1 true US20010007031A1 (en) | 2001-07-05 |
US6376511B2 US6376511B2 (en) | 2002-04-23 |
Family
ID=21764604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/155,509 Expired - Lifetime US6376511B2 (en) | 1996-03-29 | 1997-03-28 | 8-aminoquinolines |
Country Status (11)
Country | Link |
---|---|
US (1) | US6376511B2 (en) |
EP (1) | EP0907363B1 (en) |
AT (1) | ATE362762T1 (en) |
AU (1) | AU729992B2 (en) |
CA (1) | CA2250501C (en) |
DE (1) | DE69737749T2 (en) |
DK (1) | DK0907363T3 (en) |
ES (1) | ES2284184T3 (en) |
NZ (1) | NZ332197A (en) |
PT (1) | PT907363E (en) |
WO (1) | WO1997036590A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210150D0 (en) | 2002-05-03 | 2002-06-12 | Smithkline Beecham Plc | Process |
US6949250B2 (en) * | 2002-12-16 | 2005-09-27 | The United States Of America As Represented By The Secretary Of Agriculture | Selective algaecides for control of cyanochloronta |
WO2007127930A2 (en) * | 2006-04-28 | 2007-11-08 | Kansas State University Research Foundation | Compounds affecting gap junction activity |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB834300A (en) * | 1957-03-22 | 1960-05-04 | Wellcome Found | Improvements in and relating to quinoline derivatives and the manufacture thereof |
US4209519A (en) * | 1978-03-13 | 1980-06-24 | The United States Of America As Represented By The Secretary Of The Army | Anti-leishmanial lepidine derivatives |
US4431807A (en) * | 1980-06-12 | 1984-02-14 | The United States Of America As Represented By The Secretary Of The Army | 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines |
US4659708A (en) * | 1980-09-02 | 1987-04-21 | The United States Of America As Represented By The Secretary Of The Army | Anti-leishmanial lepidine derivatives |
US4554279A (en) * | 1981-01-29 | 1985-11-19 | The United States Of America As Represented By The Secretary Of The Army | 5-(Straight chain 3-12 carbon alkoxy)-8-quinolinamines and their use for treatment of malaria |
US4617394A (en) * | 1985-10-15 | 1986-10-14 | The United States Of America As Represented By The Secretary Of The Army | 4-methyl-5-(unsubstituted and substituted phenoxy)-2,6-dimethoxy-8-(aminoalkylamino) quinolines |
FR2612778B1 (en) * | 1987-03-24 | 1991-10-18 | Ire Cell Targ Sa | NOVEL ANTIMALARIA AMINOQUINOLEIN DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
FR2644462B1 (en) * | 1988-09-23 | 1993-07-09 | Ire Celltarg Sa | NOVEL COMPOUNDS ACTIVE ON TISSUE FORMS OF MALARIA AND PROCESS FOR PREPARING THE SAME |
US4980360A (en) * | 1990-03-13 | 1990-12-25 | Calspan Corporation | 5-(phenylalkoxy)primaquine compounds and their use for treatment of malaria |
US5104885A (en) * | 1990-03-13 | 1992-04-14 | Calspan Corporation | 5-(phenylalkoxy)primaquine and 5[(heterocycle)alkoxy] primaquine compounds and their use for treatment of malaria |
-
1997
- 1997-03-28 US US09/155,509 patent/US6376511B2/en not_active Expired - Lifetime
- 1997-03-28 PT PT97917709T patent/PT907363E/en unknown
- 1997-03-28 CA CA002250501A patent/CA2250501C/en not_active Expired - Fee Related
- 1997-03-28 EP EP97917709A patent/EP0907363B1/en not_active Expired - Lifetime
- 1997-03-28 ES ES97917709T patent/ES2284184T3/en not_active Expired - Lifetime
- 1997-03-28 DE DE69737749T patent/DE69737749T2/en not_active Expired - Fee Related
- 1997-03-28 WO PCT/US1997/005160 patent/WO1997036590A1/en active IP Right Grant
- 1997-03-28 DK DK97917709T patent/DK0907363T3/en active
- 1997-03-28 AU AU25966/97A patent/AU729992B2/en not_active Expired
- 1997-03-28 AT AT97917709T patent/ATE362762T1/en not_active IP Right Cessation
- 1997-03-28 NZ NZ332197A patent/NZ332197A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU729992B2 (en) | 2001-02-22 |
EP0907363A4 (en) | 2005-04-06 |
NZ332197A (en) | 2000-06-23 |
CA2250501A1 (en) | 1997-10-09 |
AU2596697A (en) | 1997-10-22 |
CA2250501C (en) | 2007-11-13 |
ES2284184T3 (en) | 2007-11-01 |
EP0907363A1 (en) | 1999-04-14 |
WO1997036590A1 (en) | 1997-10-09 |
DE69737749T2 (en) | 2008-01-31 |
DE69737749D1 (en) | 2007-07-05 |
DK0907363T3 (en) | 2007-09-24 |
US6376511B2 (en) | 2002-04-23 |
EP0907363B1 (en) | 2007-05-23 |
PT907363E (en) | 2007-06-08 |
ATE362762T1 (en) | 2007-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0588430B1 (en) | Use of (S)-(+)-Hydroxychloroquine | |
JP3020808B2 (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives as therapeutic agents for psychosis | |
TWI387456B (en) | Combination of ferroquine and an artemisinin derivative for the treatment of malaria | |
US6451813B1 (en) | Treatment of gastroparesis in certain patient groups | |
US6376511B2 (en) | 8-aminoquinolines | |
US5134168A (en) | Phenoxy and phenylthio, amino substituted benzocycloalkane derivatives in the treatment and prevention of drug-resistant protozoal infections | |
US20200215068A1 (en) | Treatment of type i and type ii diabetes | |
US4617394A (en) | 4-methyl-5-(unsubstituted and substituted phenoxy)-2,6-dimethoxy-8-(aminoalkylamino) quinolines | |
CA2100158A1 (en) | 3-hydroxypyridin-4-one derivatives as pharmaceutical compositions | |
FI113368B (en) | A process for the preparation of therapeutically active 2- (carboxy or urea) -4-sulfonyl- (chromenes or thiochromenes) | |
FR2725718A1 (en) | BIS-2-AMINOPYRIDINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS | |
US7183291B2 (en) | Method for the treatment of malaria by the use of primaquine derivative N1-(3-ethylidinotetrahydrofuran-2-one)-N4- (6-methoxy-8-quinolinyl)-1,4-pentanediamine as gametocytocidal agent | |
US4980360A (en) | 5-(phenylalkoxy)primaquine compounds and their use for treatment of malaria | |
US20050165068A1 (en) | Compounds, in particularly of urea derivatives or esters of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases | |
EP2727911B1 (en) | Novel means and methods for treating malaria and other parasitic disorders | |
JPH0859471A (en) | Antimalarial agent | |
EP1055427B1 (en) | Use of primaquine derivatives for the treatment of malaria | |
US20040192724A1 (en) | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | |
US6818653B1 (en) | 6,7-Disubstituted -5,8-quinolinedione derivatives as an antifungal agent | |
JP4727233B2 (en) | Ring-substituted 8-aminoquinoline derivatives as antimalarials | |
JP3638536B2 (en) | Piperazine derivatives and drug sensitivity recovery agents | |
US9499471B2 (en) | Biphenyl compounds for use in treating malaria and other parasitic disorders | |
WO1999018962A1 (en) | Pharmaceutically active compound and methods of use | |
Ashley et al. | 19 Antimalarial Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED RESEACH AND TECHNOLOGY INSTITUTE, INC., I Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARTLETT, MARILYN;REEL/FRAME:010017/0348 Effective date: 19990607 Owner name: UNIVERSITY OF MIAMI, THE, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AGER, ARBA L.;REEL/FRAME:010017/0324 Effective date: 19990603 Owner name: MISSISSIPPI, UNIVERSITY OF, THE, MISSISSIPPI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCCHESNEY, JAMES;NANAYAKKARA, DHAMMIKA N.;REEL/FRAME:010028/0679;SIGNING DATES FROM 19990106 TO 19990416 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |